AcuCort
AcuCort receives renewed marketing authorisation for Zeqmelit® in Norway
AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.
For further information:
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.
| Datum | 2025-03-19, kl 13:14 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.